RE:RE:RE:Serious question....Monteviale wrote: @ Prof.... I agree with what you said except that aphria no longer gets a royalty from LHS. In order to list on the NYSE and stay in good standing with TSX they had to stop accepting royalty pymts from LHS. LHS gets the benefit of using the Aphria brand name for free.
A similar question @ https://www.stockhouse.com/companies/bullboard/t.apha/aphria-inc?postid=29031343 was asked by another poster, but there was no reply. Please feel free to share your opinions. Basically, the question is quoted as follows:
"
LHS was part of APHA's assets until LHS was divested in September 2018. Would there be any effect to the the sales number in the APHA's upcoming quarterly result to be released in January 2019? I believe LHS is still selling products from APHA ..... but not sure how the numbers are reflected (if ever) on the financial statements (pre-divestment vs post-divestment)
"
I am interested in knowing as well since LHS was expliciting mentioned in the most recent earnings NR. See https://www.stockhouse.com/news/press-releases/2018/10/12/aphria-records-solid-revenue-growth-in-first-quarter-of-2019
"
The increase in net income for the quarter relates to gains on our long-term investment portfolio, primarily our investments in Liberty Health Sciences and Hiku Brands Company Ltd. and the increase in fair value of biological assets caused by the production increase associated with our Part III Expansion project.
"